Personalized mesenchymal stem Cells / Immorta Bio - LARVOL DELTA

How artificial intelligence can enable personalized mesenchymal stem cell-based therapeutic strategies in systemic lupus erythematosus. (PubMed, Front Immunol) - "Moreover, AI enables the analysis of extensive datasets to refine dosing strategies and improve the integration of MSC therapy with immunosuppressants. By enhancing the precision, consistency, and personalisation of MSC-based interventions, AI has the potential to significantly improve therapeutic outcomes in SLE, advancing the field toward more effective and patient-centred autoimmune disease management."

Journal • Review • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Immorta Bio's Anti-Aging Stem Cell Product Shows Superiority in Rheumatoid Arthritis in Preclinical Studies (PRNewswire) - "Immorta Bio Inc...announced today that it has published, in the Peer-Reviewed Journal of Stem Cell Research & Therapeutics, data demonstrating that intravenous injection of the Company's proprietary Personalized Mesenchymal Stem Cells (pMSC) successfully treats rheumatoid arthritis in the collagen-induced arthritis (CIA) model. In head-to-head preclinical comparisons, Immorta Bio's pMSC significantly outperformed standard bone marrow and umbilical cord derived MSCs in reducing arthritis scores and paw swelling, highlighting their enhanced immunomodulatory and regenerative potential."

Preclinical